Coexpression of aPKCλ/ι and IL-6 in prostate cancer tissue correlates with biochemical recurrence

Cancer Science

Volumn 102, Issue 8, 2011, Pages 1576-1581

  Ishiguro, Hitoshi ^a,b   Akimoto, Kazunori ^a   Nagashima, Yoji ^a,c   Kagawa, Eriko ^a   Sasaki, Takeshi ^c   Sano, Jin yu ^d   Takagawa, Ryo ^a   Fujinami, Kiyoshi ^a   Sasaki, Kazunori ^a   Aoki, Ichiro ^a,c   Ohno, Shigeo ^a,c   Kubota, Yoshinobu ^a,c   Uemura, Hiroji ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KANAGAWA ACADEMY OF SCIENCE AND TECHNOLOGY   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

^d Chigasaki Municipal Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE C IOTA; PROTEIN KINASE C LAMBDA;

AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CANCER TISSUE; CORRELATIONAL STUDY; DISEASE SEVERITY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION;

ADULT; AGED; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; ISOENZYMES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; PROTEIN KINASE C;

EID: 79960437289     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01972.x     Document Type: Article

References (38)

1. Jamal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Tabata N, Ohno Y, Matsui R et al. Partial cancer prevalence in Japan up to 2020: estimates based on incidence and survival data from population-based cancer registries. Jpn J Clin Oncol 2008; 38: 146-57.
3. Mao HL, Zhu ZQ, Chen CD. The androgen receptor in hormone-refractory prostate cancer. Asian J Androl 2009; 11: 69-73.
4. Kaarbø M, Klokk TI, Saatcioglu F. Androgen signaling and its interactions with other signaling pathways in prostate cancer. Bioessays 2007; 29: 1227-38.
5. Vishnu P, Tan WW. Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther 2010; 3: 39-51.
6. Attard G, Sarker D, Reid A, Molife R, Parker C, de Bono JS. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer 2006; 95: 767-74.
7. Akimoto K, Mizuno K, Osada S et al. A new member of the third class in the protein kinase C family, PKC lambda, expressed dominantly in an undifferentiated mouse embryonal carcinoma cell line and also in many tissues and cells. J Biol Chem 1994; 269: 12677-83.
8. Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 1995; 9: 484-96.
9. Akimoto K, Takahashi R, Moriya S et al. EGF and PDGF receptors activate atypical PKCλ through phosphatidylinositol 3-kinase. EMBO J 1996; 15: 788-98.
10. Suzuki A, Akimoto K, Ohno S. Protein kinase C λ/ι (PKCλ/ι: aPKC isotype essential for the development of multicellular organism. J Biochem 2003; 133: 9-16.
11. Moscat J, Diaz-Meco MT, Albert A, Campuzano S. Cell signaling and function organized by PB1 domain interactions. Mol Cell 2006; 23: 631-40.
12. Ishiguro H, Akimoto K, Nagashima Y et al aPKCλ/ι promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. Proc Natl Acad Sci USA 2009; 106: 16369-74.
13. Regala RP, Weems C, Jamieson L et al. Atypical protein kinase C ι is an oncogene in human non-small cell lung cancer. Cancer Res 2005; 65: 8905-11.
14. Zhang L, Huang J, Yang N et al. Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res 2006; 66: 4627-35.
15. Eder AM, Sui X, Rosen DG et al. Atypical PKC iota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102: 12519-24.
16. Kojima Y, Akimoto A, Nagashima Y et al. The overexpression and altered localization of the atypical protein kinase C λ/ι in breast cancer correlates with the pathologic type of these tumors. Hum Pathol 2008; 39: 824-31.
17. Takagawa R, Akimoto K, Ichikawa Y et al. High expression of atypical protein kinase C l/I in gastric cancer as a prognostic factor for recurrence. Ann Surg Oncol 2010; 17: 81-8.
18. Li Q, Wang JM, Liu C, Xiao BL, Lu JX, Zou SQ. Correlation of aPKC-iota and E-cadherin expression with invasion and prognosis of cholangio-carcinoma. Hepatobiliary Pancreat Dis Int 2008; 7: 70-5.
19. Patel R, Win H, Desai S, Patel K, Matthews JA, Acevedo-Duncan M. Involvement of PKC-iota in glioma proliferation. Cell Prolif 2008; 41: 122-35.
20. Regala RP, Weems C, Jamieson L, Copland JA, Thompson EA, Fields AP. Atypical protein kinase Cι plays a critical role in human lung cancer cell growth and tumorigenicity. J Biol Chem 2005; 280: 31109-15.
21. Murray NR, Jamieson L, Yu W et al. Protein kinase C is required for Ras transformation and colon carcinogenesis in vivo. J Cell Biol 2004; 164: 797-802.
22. Baldwin RM, Parolin DA, Lorimer IA. Regulation of glioblastoma cell invasion by PKC iota and RhoB. Oncogene 2008; 27: 3587-95.
23. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007; 110: 1911-28.
24. Nakashima J, Tachibana M, Horiguchi Y et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000; 6: 2702-6.
25. George DJ, Halabi S, Shepard TF et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res 2005; 11: 1815-20.
26. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997; 57: 141-6.
27. Culig Z, Bartsch G, Hobisch A. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol Cell Endocrinol 2002; 197: 231-8.
28. Cookson MS, Aus G, Burnett AL et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007; 177: 540-5.
29. Sobin LH, Gospodariwicz M, Wittekind CH, eds. International Union Against Cancer (UICC): TNM Classification of Malignant Tumours, 7th edn. New York: Wiley-Blackwell, 2009; 243-8.
30. Sasaki T, Ryo A, Uemura H et al. An immunohistochemical scoring system of prolyl isomerase Pin1 for predicting relapse of prostate carcinoma after radical prostatectomy. Pathol Res Pract 2006; 202: 357-64.
31. Royuela M, Ricote M, Parsons MS, García-Tuñón I, Paniagua R, de Miguel MP. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate. J Pathol 2004; 202: 41-9.
32. Hobisch A, Rogatsch H, Hittmair A et al. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 2000; 191: 239-44.
33. Tam L, McGlynn LM, Traynor P, Mukherjee R, Bartlett JMS, Edwards J. Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer 2007; 97: 378-83.
34. Wallner L, Dai J, Escara-Wilke J et al. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res 2006; 66: 3087-95.
35. Xu DD, Sun SD, Wang F et al. Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy. J Urol 2009; 74: 654-9.
36. Isbarn H, Wanner M, Salomon G et al. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. BJU Int 2010; 106: 37-43.
37. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001; 58: 1008-15.
38. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001; 12: 375-91.